AES

HASI Invests in 605 MW Renewables Portfolio Owned and Operated by AES

Retrieved on: 
Thursday, January 4, 2024

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240104710826/en/
    Pictured: Illustrative solar and solar-plus-storage projects included in the HASI and AES renewables portfolio.
  • In January 2023, HASI announced a common equity investment with AES in an approximately 1.3-GW portfolio of operating utility-scale solar and wind projects.
  • Additionally, HASI and AES' clean energy business in the U.S. have a six-year track record of successful solar land transactions.
  • “HASI is immensely proud to advance our partnership with AES with this latest transaction,” said Susan Nickey, Chief Client Officer of HASI.

Eisai to Present Latest Data on Perampanel at The 77th American Epilepsy Society (AES) Annual Meeting

Retrieved on: 
Wednesday, November 22, 2023

Major presentations include the design and outcomes of a clinical research evaluating the safety of perampanel versus placebo (Poster No.

Key Points: 
  • Major presentations include the design and outcomes of a clinical research evaluating the safety of perampanel versus placebo (Poster No.
  • 1.493), and the data of evaluating the effects of perampanel on cognitive function and sleep (Poster No.
  • Eisai pursues its mission to provide "seizure freedom" to a greater number of patients with epilepsy.
  • Eisai remains committed further to addressing the diverse needs of, and increasing the benefits provided to, patients with epilepsy and their families.

ASEAN Ceramics 2023: the premier trade fair for Ceramics - Machinery, Technology and Materials professionals in Southeast Asia

Retrieved on: 
Friday, November 17, 2023

The event is organized by Messe Munchen, a leading international trade fair organizer, and is expected to attract thousands of exhibitors and visitors from around the world.

Key Points: 
  • The event is organized by Messe Munchen, a leading international trade fair organizer, and is expected to attract thousands of exhibitors and visitors from around the world.
  • Vietnam, 10 November 2023 - ASEAN Ceramics, Southeast Asia's leading international exhibition of machinery, technology and materials for manufacturing white-ware, heavy clay, bricks and advanced ceramics, will open its doors on Tuesday, 28 November in Hanoi.
  • The Department of Silicate Materials Technology, School of Chemistry and Life Sciences, Hanoi University of Science and Technology have partnered with ASEAN Ceramics to launch the Ceramic Job and Education Fair.
  • The ASEAN Ceramics Conference will take place on 28 - 30 November in parallel to the with the trade fair.

New SSA Commissioner Faces Unprecedented Disability Applications Backlog, Allsup Explains

Retrieved on: 
Friday, December 22, 2023

“We are optimistic about his leadership, especially in dealing with the extensive backlog of SSDI applications.

Key Points: 
  • “We are optimistic about his leadership, especially in dealing with the extensive backlog of SSDI applications.
  • Allsup and Allsup Employment Services (AES), a Social Security-authorized Employment Network, utilize technology and expertise in these programs to empower individuals with disabilities.
  • In addition, veterans can benefit with VA-Accredited Claims Agents through the Allsup Veterans Disability Appeal Services® in receiving VA disability compensation.
  • Allsup services now include financial solutions to help with near-term urgent needs during the SSA wait through its exclusive Disability Financial Solutions℠ .

Arqit, BT, and Fortinet Launch Quantum-Safe VPN to Protect Against Evolving Cyberthreats

Retrieved on: 
Thursday, December 14, 2023

This announcement follows the successful trial of quantum-safe tunnels between three BT sites in London, Exeter, and Adastral Park in Suffolk.

Key Points: 
  • This announcement follows the successful trial of quantum-safe tunnels between three BT sites in London, Exeter, and Adastral Park in Suffolk.
  • As cyberthreats evolve and become increasingly sophisticated, organisations worldwide need to ensure they can defend their data and communications against both existing and upcoming threats.
  • The solution provides quantum-safe symmetric keys that can be created and rotated on-demand to encrypt and protect sensitive data between point-to-point VPN links.
  • By integrating our cloud-based software into Fortinet firewalls, combined with a BT managed service, we've made this an easy step for organisations already using Fortinet solutions.

Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2023)

Retrieved on: 
Saturday, December 2, 2023

VANCOUVER, British Columbia, Dec. 02, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will provide updates on its neurology programs at the Annual Meeting of the American Epilepsy Society (AES 2023).

Key Points: 
  • VANCOUVER, British Columbia, Dec. 02, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will provide updates on its neurology programs at the Annual Meeting of the American Epilepsy Society (AES 2023).
  • Importantly, we are looking forward to presenting new interim data from our ongoing open-label extension study from our Phase 2b X-TOLE trial.
  • The exhibit will also feature the topline results from the Phase 2 proof-of-concept X-NOVA clinical trial in major depressive disorder.
  • Posters will be added to the Xenon website consistent with AES 2023 conference guidelines.

NeuroPace and the RNS System Showcased at the 77th American Epilepsy Society (AES) Annual Meeting

Retrieved on: 
Friday, December 1, 2023

“The Society’s annual meeting is the largest conference in the field of epilepsy in the U.S.,” said Martha Morrell, M.D., NeuroPace’s Chief Medical Officer.

Key Points: 
  • “The Society’s annual meeting is the largest conference in the field of epilepsy in the U.S.,” said Martha Morrell, M.D., NeuroPace’s Chief Medical Officer.
  • “We look forward to collaborating with the many healthcare providers, scientists, and others from all over the world who are gathering in Orlando to promote better outcomes for people with epilepsy.
  • We will host various presentations and events highlighting our RNS System and look forward to engaging with the broader scientific community in the epilepsy field.”
    Over 50 original scientific presentations and posters regarding the RNS System will be presented throughout the meeting, as well as a number of general meeting sessions that include how the RNS System provides an important therapy option for the treatment of drug resistant epilepsy.
  • These presentations, posters, and events involve key opinion leaders as well as early career scientists and clinicians, all of whom aim to improve the lives of patients living with drug-resistant epilepsy.

Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)

Retrieved on: 
Friday, December 1, 2023

and Chief Medical Officer of Ovid Therapeutics.

Key Points: 
  • and Chief Medical Officer of Ovid Therapeutics.
  • “GABA-AT is a validated target in seizure reduction that has been limited in clinical use to date.
  • Title: Blocking of GABA-AT Activity by OV329 Selectively Alters Tonic and Phasic Inhibition in Dentate Gyrus Granule Cells.
  • Title: Low, Repeat Dosing of OV329 Enhances GABA-AT Inhibition in Rodent Brain: Relationship between Pharmacokinetic (PK) and Pharmacodynamic (PD) Effects.

Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting

Retrieved on: 
Friday, December 1, 2023

MIAMI, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Amy Chappell, M.D., FAAN, will be presenting preclinical in vivo data evaluating BAER-101 using the SynapCell's Genetic Absence Epilepsy Rat from Strasbourg (“GAERS”) model of absence epilepsy at the American Epilepsy Society (AES) 2023 Annual Meeting in Orlando, FL on December 2, 2023.

Key Points: 
  • MIAMI, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Amy Chappell, M.D., FAAN, will be presenting preclinical in vivo data evaluating BAER-101 using the SynapCell's Genetic Absence Epilepsy Rat from Strasbourg (“GAERS”) model of absence epilepsy at the American Epilepsy Society (AES) 2023 Annual Meeting in Orlando, FL on December 2, 2023.
  • The Company's presentation details are as follows:
    “We are pleased with the progress made with BAER-101, a molecule with unique pharmacology which has demonstrated that it can significantly suppress seizures in a translational animal model of absence epilepsy,” said Alexandra MacLean, M.D., Chief Executive Officer of Avenue.
  • In the model, BAER-101 demonstrated full suppression of seizure activity with a minimal effective dose of 0.3 mg/kg, PO.
  • The combination of safety and tolerability in hundreds of patients and the preclinical efficacy data support BAER-101’s continued development in a Phase 2a trial.

GeneDx Presents New Data at the American Epilepsy Society Annual Meeting Demonstrating That Exome Sequencing Outperforms Multi-Gene Panels for Patients with Epilepsy

Retrieved on: 
Friday, December 1, 2023

The gap in diagnosis between exome sequencing and the multi-gene epilepsy panels can be largely attributed to the fact that more than half (57%) of seizure-related genes are not included on many commercially available epilepsy panels.

Key Points: 
  • The gap in diagnosis between exome sequencing and the multi-gene epilepsy panels can be largely attributed to the fact that more than half (57%) of seizure-related genes are not included on many commercially available epilepsy panels.
  • Of those patients with a positive genetic diagnosis from exome sequencing, 11% had a variant in a treatment related gene.
  • GeneDx will also present data at the conference that shows insurance may offer better coverage for exome sequencing than multi-gene panels for patients with epilepsy.
  • At the conference, GeneDx will also be hosting an industry sponsored symposium discussing the ways in which exome sequencing can help epilepsy patients find answers sooner.